SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD) announced today it has initiated a research program to test the capabilities of the Aethlon Hemopurifier® to identify and capture Cytomegalovirus (CMV). The Hemopurifier® is a first-in-class medical device that assists the immune response in combating infectious disease through real-time therapeutic filtration of infectious viruses and immunosuppressive proteins from the entire circulatory system. Safety of the Hemopurifier® has been demonstrated in multi-site human studies, with robust viral load reductions observed in enrolled Hepatitis-C (HCV) infected patients. Safety and efficacy data resulting from the first use of the Hemopurifier® in an individual infected with Human Immunodeficiency Virus (HIV) is forthcoming.
